Loading…
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-28M | $-26M | $-16M | -143.6% | - | - |
| 2024 | $0M | $-20M | $-19M | $-12M | -195.6% | - | - |
| 2023 | $0M | $-23M | $-22M | $-16M | -182.4% | - | - |
| 2022 | $0M | $-19M | $-19M | $-14M | -134.2% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 |
| Operating Expense | 19.23 | 22.90 | 19.85 | 27.57 |
| Operating Income | -19.23 | -22.90 | -19.85 | -27.57 |
| EBITDA | -19.23 | -22.90 | -19.85 | -27.57 |
| EBIT | -19.23 | -22.90 | -19.85 | -27.57 |
| Pretax Income | -19.09 | -22.26 | -19 | -26.44 |
| Net Income | -19.09 | -22.26 | -19 | -26.44 |
| Net Income Common Stockholders | -19.09 | -22.26 | -19 | -28.87 |
| Total Expenses | 19.23 | 22.90 | 19.85 | 27.57 |
| Interest Income | 0.15 | 0.64 | 0.85 | 1.13 |
| Research And Development | 13.23 | 15.38 | 12.92 | 18.15 |
| Selling General And Administration | 6.01 | 7.52 | 6.93 | 9.42 |
| Normalized EBITDA | -19.23 | -22.90 | -19.85 | -27.57 |
| Normalized Income | -19.09 | -22.26 | -19 | -26.44 |
| Basic EPS | -1.51 | -1.43 | -1.11 | 0 |
| Diluted EPS | -1.51 | -1.43 | -1.11 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Net Income From Continuing Operation Net Minority Interest | -19.09 | -22.26 | -19 | -26.44 |
| Net Interest Income | 0.15 | 0.64 | 0.85 | 1.13 |
| Net Income From Continuing And Discontinued Operation | -19.09 | -22.26 | -19 | -26.44 |
| Total Operating Income As Reported | -19.23 | -22.90 | -19.85 | -27.57 |
| Diluted Average Shares | 12.66 | 15.56 | 17.11 | 0 |
| Basic Average Shares | 12.66 | 15.56 | 17.11 | 0 |
| Diluted NI Availto Com Stockholders | -19.09 | -22.26 | -19 | -28.87 |
| Otherunder Preferred Stock Dividend | 0 | 0 | 0 | 2.43 |
| Net Income Including Noncontrolling Interests | -19.09 | -22.26 | -19 | -26.44 |
| Net Income Continuous Operations | -19.09 | -22.26 | -19 | -26.44 |
| Net Non Operating Interest Income Expense | 0.15 | 0.64 | 0.85 | 1.13 |
| Interest Income Non Operating | 0.15 | 0.64 | 0.85 | 1.13 |
| General And Administrative Expense | 6.01 | 7.52 | 6.93 | 9.42 |
| Other Gand A | 3.07 | 4.38 | 4.23 | 6.40 |
| Insurance And Claims | 1.18 | 0.84 | 0.61 | 0.60 |
| Salaries And Wages | 1.76 | 2.30 | 2.09 | 2.42 |
| Operating Revenue | 0 | 0 | 0 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Nuvectis Pharma, Inc.this co. | NVCT | $235M | - | 11.85 | -143.6% | - |
| Inhibikase Therapeutics, Inc. | IKT | $246M | - | 1.83 | -27.9% | -3.01 |
| 908 Devices Inc. | MASS | $243M | - | 1.64 | 13.6% | -6.49 |
| Carlsmed, Inc. | CARL | $240M | - | 2.38 | -30.0% | -4.74 |
| Arcturus Therapeutics Holdings Inc. | ARCT | $239M | - |
| 1.12 |
| -30.7% |
| -0.45 |
| Spok Holdings, Inc. | SPOK | $229M | 14.73 | 1.56 | 10.8% | 8.93 |
| Heron Therapeutics, Inc. | HRTX | $224M | - | 16.76 | -140.9% | -1425.96 |
| Voyager Therapeutics, Inc. | VYGR | $220M | - | 1.10 | -61.1% | -0.46 |
| Keros Therapeutics, Inc. | KROS | $220M | 4.83 | 0.72 | 28.7% | -0.72 |
| Peer Median | - | 9.78 | 1.60 | -28.9% | -1.86 | |